Bright Minds Bioscienes Announces Receipt of NASDAQ Deficiency Letter Regarding Independent Director and Audit Committee Requirements
Vancouver, British Columbia, February 8, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a letter (the “Deficiency Letter”) from the Nasdaq Stock Market LLC (“NASDAQ”) dated February 2, 2023, stating that following the resignation of Dr. Williamson from the Company’s board of directors and audit…
